Clinical Impact of 18FDG-PET/CT in the Follow-up of Endometrial Cancer

2009 ◽  
Vol 15 (6) ◽  
pp. 463-466
Author(s):  
Raja Sfar ◽  
Amina Khiar ◽  
Marc Pocard ◽  
Rachid Kaci ◽  
Abdel Benada ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Clinical Impact ◽  
18Fdg Pet ◽  
Pet Ct

scholarly journals Para-aortic Lymph Node Invasion in High-risk Endometrial Cancer: Performance of 18FDG PET-CT

2019 ◽  
Vol 39 (2) ◽  
pp. 619-625 ◽  
Author(s):  
MAXIME LEGROS ◽  
FRANÇOIS MARGUERITTE ◽  
ANTOINE TARDIEU ◽  
ELISE DELUCHE ◽  
VALERE BELLE MBOU ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Lymph Node ◽  
High Risk ◽  
18Fdg Pet ◽  
Pet Ct ◽  
Aortic Lymph Node

Clinical impact of 11C-Choline PET/CT in selection and outcome of salvage cryoablation in patients with recurrent prostate cancer after radiotherapy.

2016 ◽  
Vol 34 (2_suppl) ◽  
pp. 276-276
Author(s):  
Marleen Suzanne Vallinga ◽  
Anthonius Breeuwsma ◽  
Maxim Rybalov ◽  
Jan Pruim ◽  
Igle J. De Jong
Keyword(s):  
Prostate Cancer ◽  
Hormonal Therapy ◽  
Biochemical Recurrence ◽  
Clinical Impact ◽  
Recurrent Prostate Cancer ◽  
Choline Pet ◽  
Pet Ct ◽  
Psa Response ◽  
The Impact

276 Background: Salvage cryoablation is an effective but toxic treatment for local recurrent prostate cancer after primary radiotherapy. To assess the location of recurrent prostate cancer, an 11C-choline PET/CT can be used. We studied the clinical impact of 11C-choline PET/CT on the choice for and the results of salvage cryoablation. Methods: A total of 141 patients with a biochemical recurrence (BCR according to ASTRO-Phoenix criteria) after radiotherapy, and thus candidates for salvage cryoablation, were included. Patients were re-staged with an 11C-choline PET/CT, complementary prostate biopsies, when indicated a pelvic lymph node dissection and/or additional imaging. Change in choice of therapy was defined as major (no salvage cryoablation because of metastases or lack of local recurrence on PET/CT), minor (local salvage treatment was performed, but different technique of after additional diagnostics) or none (salvage cryoablation was performed). The impact of selection of patients for cryoablation with PET/CT on outcome was measured by time from cryoablation to BCR (according to Astro-Phoenix), first distant metastasis and start of hormonal therapy. Results: In 71 of 141 patients (51%) a change in therapy was implemented because of the result of 11C-choline PET/CT. A major impact was observed in 48 (34%) patients. In 83 patients, a salvage cryoablation was performed (59%). 18% of this group showed no PSA response. Of the remaining patients with PSA response, 37% developed a BCR after mean 25.7 months. 47% of patients are still in remission after a mean follow-up of 43 months. In 16 of 83 patients (19%) metastases were proven after mean 55.4 months (SD 26.3). 15 patients started with hormonal therapy, mean 29.5 months (SD 20.1) after cryoablation. Conclusions: 11C-choline PET/CT showed a significant impact on selection for salvage cryoablation. The choice for local salvage therapy was abandoned in 34% of patients. Of the men who underwent a salvage cryoablation, 47% stayed free of biochemical recurrence during mean 43 months follow-up.

scholarly journals Comparison of Assesment of Imaging Response with Magnetic Resonance (MR) and 18fdg-PET/TC in Multiple Myeloma (MM). Single Centre Experience

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 5707-5707
Author(s):  
Adrian Alegre ◽  
Beatriz Aguado ◽  
Miriam González-Pardo ◽  
Evelyn Acuña ◽  
Álvaro Arriero ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Magnetic Resonance ◽  
Bone Involvement ◽  
Whole Body ◽  
Advisory Committees ◽  
Leptomeningeal Involvement ◽  
18Fdg Pet ◽  
Pet Ct

Abstract Introduction: Conventional radiography remains the “gold standard” technique for bone involvement assessment in patients with multiple myeloma (MM). Newer imaging modalities such as whole-body Magnetic Resonance (MR) and 18FDG-PET/CT have emerged as more sensitive techniques than routine skeletal survey in the detection of bone involvement in the diagnostic and follow up of patients with MM. The advantages and disadvantages of MR and 18FDG-PET/CT are discussed. Patients and methods: We have retrospectively analyzed 12 patients since 2012 to 2014 with multiple myeloma in our institution whose bone involvement was evaluated with MR and 18FDG-PET/CT. Age range: 36-70. Seven patients were female and five were male. Eight cases were treated with an induction regimen containing bortezomib, three cases with chemotherapy with alternating VBCMP/VBAD and one of them with VAD. After induction, ten of them received autologous stem cell transplantation (ASCT), one patient allogeneic stem cell transplantation and one patient no transplantation. Results: All patients presented bone lesions on MR and all of them were also positive at PET/CT. One showed leptomeningeal involvement on RM and PET. Regarding extramedullar disease two patients presented soft tissue masses and in other two cases there was ganglionar involvement, all of them positives by both techniques. Of nine evaluable patients after complete treatment, six of them have a negative PET and three have a low positive SUV value, however eight of them still had persistent residual lesions on MR, what could indicate not stringent complete response. The patient with leptomeningeal involvement had both MR and PET negative result after treatment. Comments and conclusions: Our data suggest that whole-body MR and 18FDG-PET/CT provide valuable complementary information, MR could be superior to assess extent of lesions and PET to monitor disease activity and to detect asymptomatic relapse. The optimal imaging technique for the management of patients with MM is not well defined and our proposal is a multimodality imaging approach according to individualized criteria. References: Caers J et al. The role of positron emission tomography-computed and magnetic resonance imaging in diagnosis and follow-up of multiple myeloma. Haematologica 2014;99(4):629-637. doi:10.3324/haematol.2013.091918. Agarwal A et al. Evolving Role of FDG PET/CT in Multiple Myeloma Imaging and Management. AJR 2013;200:884-890. Dimopoulos D et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia 2009, 1–12. doi:10.1038/leu.2009.89 Disclosures Alegre: Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Jansen: Membership on an entity's Board of Directors or advisory committees, Research Funding.

18FDG-PET/CT for Treatment Planning and Follow-Up

2007 ◽  
pp. 55-61
Author(s):  
Medhat M. Osman ◽  
Allison Wall ◽  
Matthew D. Miller ◽  
Nghi Nguyen ◽  
Dana A. Oliver ◽  
...  
Keyword(s):  
Treatment Planning ◽  
18Fdg Pet ◽  
Pet Ct

scholarly journals 18FDG-PET/CT is useful in the follow-up of surgically treated patients with oesophageal adenocarcinoma

2017 ◽  
pp. 20170341 ◽  
Author(s):  
Sonia L Betancourt Cuellar ◽  
Diana P Palacio ◽  
Carol C Wu ◽  
Brett W Carter ◽  
Arlene M Correa ◽  
...  
Keyword(s):  
Oesophageal Adenocarcinoma ◽  
18Fdg Pet ◽  
Pet Ct

Safety and cost analysis of an 18FDG-PET-CT response based follow-up strategy for head and neck cancers treated with primary radiation or chemoradiation

Oral Oncology ◽  
2015 ◽  
Vol 51 (5) ◽  
pp. 529-535 ◽  
Author(s):  
Ketan Shah ◽  
Luc te Marvelde ◽  
Marnie Collins ◽  
Richard De Abreu Lourenco ◽  
Ieta D’Costa ◽  
...  
Keyword(s):  
Cost Analysis ◽  
Head And Neck ◽  
Head And Neck Cancers ◽  
Primary Radiation ◽  
18Fdg Pet ◽  
Pet Ct

SUVmax of 18FDG PET/CT as a predictor of high-risk endometrial cancer patients

2013 ◽  
Vol 129 (2) ◽  
pp. 298-303 ◽  
Author(s):  
Sofie Leisby Antonsen ◽  
Annika Loft ◽  
Rune Fisker ◽  
Anne Lerberg Nielsen ◽  
Erik Søgaard Andersen ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
High Risk ◽  
Cancer Patients ◽  
18Fdg Pet ◽  
Pet Ct

scholarly journals Role of 18FDG-PET/CT in detecting relapse during follow-up of patients with Hodgkin’s lymphoma

2009 ◽  
Vol 88 (12) ◽  
pp. 1229-1236 ◽  
Author(s):  
R. Crocchiolo ◽  
F. Fallanca ◽  
G. Giovacchini ◽  
A. J. M. Ferreri ◽  
A. Assanelli ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
18Fdg Pet ◽  
Pet Ct
Sign in / Sign up

Export Citation Format

Share Document